relatlimab
Selected indexed studies
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. (N Engl J Med, 2022) [PMID:34986285]
- Relatlimab-nivolumab: A practical overview for dermatologists. (J Am Acad Dermatol, 2023) [PMID:37343829]
- Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. (Eur J Cancer, 2025) [PMID:40513285]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Nivolumab Plus Relatlimab: First Approval. (2022) pubmed
- Relatlimab-nivolumab: A practical overview for dermatologists. (2023) pubmed
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. (2022) pubmed
- Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. (2025) pubmed
- Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. (2023) pubmed
- Neoadjuvant relatlimab and nivolumab in resectable melanoma. (2022) pubmed
- Nivolumab and relatlimab for the treatment of melanoma. (2023) pubmed
- Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY. (2023) pubmed
- Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy. (2023) pubmed
- Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma. (2023) pubmed